PDF herunterladen
TumorDiagnostik & Therapie 2022; 43(06): 381-385
DOI: 10.1055/a-1743-6451
Übersicht
Schwerpunkt

Medulläres Schilddrüsenkarzinom

Matthias Kroiss
1   Medizinische Klinik und Poliklinik IV, LMU Klinikum, Ludwig-Maximilians-Universität München, Deutschland
2   Schwerpunkt Endokrinologie/Diabetologie, Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg
,
Viktoria Florentine Koehler
1   Medizinische Klinik und Poliklinik IV, LMU Klinikum, Ludwig-Maximilians-Universität München, Deutschland
3   Medizinische Klinik I, Schwerpunkte Diabetologie/Endokrinologie, Johann-Wolfgang-Goethe-Universität, Frankfurt, Deutschland
,
Christine Spitzweg
1   Medizinische Klinik und Poliklinik IV, LMU Klinikum, Ludwig-Maximilians-Universität München, Deutschland
4   Adjunct Academic Appointment, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic Rochester, MN, USA
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Schlüsselwörter

RET-Gen - Mutation - Tyrosinkinase-Inhibitoren - Molekularpathologie - Calcitonin

Key words

RET gene - mutation - tyrosine kinase inhibitors - molecular pathology - calcitonin


Publikationsverlauf

Artikel online veröffentlicht:
03. August 2022

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Randle RW, Balentine CJ, Leverson GE. et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017; 161: 137-146
    CrossrefPubMedSuche in Google Scholar
  • 2 Mathiesen JS, Kroustrup JP, Vestergaard P. et al. Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997–2014: A Nationwide Study. Thyroid 2019; 29: 368-377
    CrossrefPubMedSuche in Google Scholar
  • 3 Kim SH, Kim BS, Jung SL. et al. Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol 2009; 10: 101-105
    CrossrefPubMedSuche in Google Scholar
  • 4 Lee S, Shin JH, Han BK. et al. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. Am J Roentgenol 2010; 194: 1090-1094
    CrossrefPubMedSuche in Google Scholar
  • 5 Woliński K, Rewaj-Łosyk M, Ruchała M. Sonographic features of medullary thyroid carcinomas – a systematic review and meta-analysis. Endokrynol Pol 2014; 65: 314-318
    CrossrefPubMedSuche in Google Scholar
  • 6 Allelein S, Ehlers M, Morneau C. et al. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Horm Metab Res 2018; 50: 23-28
    Thieme ConnectPubMedSuche in Google Scholar
  • 7 Frank-Raue K, Schott M, Raue F. [Recommendation for Calcitonin Screening in Nodular Goiter]. Dtsch Med Wochenschr 2018; 143: 1065-1069
    Thieme ConnectPubMedSuche in Google Scholar
  • 8 Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. The Journal of clinical endocrinology and metabolism 2010; 95: 2655-2663
    CrossrefPubMedSuche in Google Scholar
  • 9 Torresan F, Mian C, Cavedon E. et al. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening. Langenbeckʼs archives of surgery 2019; 404: 411-419
    CrossrefPubMedSuche in Google Scholar
  • 10 Machens A, Dralle H. Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 2016; 175: 219-228
    CrossrefPubMedSuche in Google Scholar
  • 11 Wells Jr SA, Asa SL, Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25: 567-610
    CrossrefPubMedSuche in Google Scholar
  • 12 Margraf RL, Crockett DK, Krautscheid PM. et al. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 2009; 30: 548-556
    CrossrefPubMedSuche in Google Scholar
  • 13 ARUP Laboratories. Mutation Databases – Multiple Endocrine Neoplasia type 2 (MEN2) and RET. Im Internet (Stand: 14.10.2021): http://arup.utah.edu/database/MEN2 / MEN2_welcome.php
    PubMed
  • 14 Ciampi R, Romei C, Ramone T. et al. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. iScience 2019; 20: 324-336
    CrossrefPubMedSuche in Google Scholar
  • 15 Romei C, Ciampi R, Casella F. et al. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget 2018; 9: 9875-9884
    CrossrefPubMedSuche in Google Scholar
  • 16 Raue F, Frank-Raue K. Long-Term Follow-up in Medullary Thyroid Carcinoma. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2015; 204: 207-225
    CrossrefPubMedSuche in Google Scholar
  • 17 Kwon H, Kim WG, Jeon MJ. et al. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. Endocrine 2016; 53: 174-181
    CrossrefPubMedSuche in Google Scholar
  • 18 Machens A, Hofmann C, Hauptmann S. et al. Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results. Eur J Endocrinol 2007; 157: 85-93
    CrossrefPubMedSuche in Google Scholar
  • 19 Machens A, Lorenz K, Dralle H. Prediction of biochemical cure in patients with medullary thyroid cancer. Br J Surg 2020; 107: 695-704
    CrossrefPubMedSuche in Google Scholar
  • 20 Machens A, Dralle H. Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg 2013; 257: 751-757
    CrossrefPubMedSuche in Google Scholar
  • 21 Schlumberger M, Bastholt L, Dralle H. et al. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J 2012; 1: 5-14
    CrossrefPubMedSuche in Google Scholar
  • 22 Elisei R, Schlumberger MJ, Müller SP. et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639-3646
    CrossrefPubMedSuche in Google Scholar
  • 23 Wells Jr SA, Robinson BG, Gagel RF. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141
    CrossrefPubMedSuche in Google Scholar
  • 24 Koehler VF, Berg E, Adam P. et al. Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. Thyroid 2021;
    CrossrefPubMedSuche in Google Scholar
  • 25 Subbiah V, Hu MI, Wirth LJ. et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 2021; 9: 491-501
    CrossrefPubMedSuche in Google Scholar